Lasers and injectables for diabetic retinal disease

Dis Mon. 2021 May;67(5):101143. doi: 10.1016/j.disamonth.2021.101143. Epub 2021 Jan 26.

Authors

Mark Solinski¹, Lisa Leishman², Veena Raiji³

Affiliations

¹ Department of Ophthalmology, Loyola University Medical Center, Maywood, Illinois.
² Retina Consultants, 2454 E Dempster St. Ste. 400, Des Plaines, IL, 60016 (847) 299-0700; Cook County Hospital, Ophthalmology Dept., Chicago, IL.
³ Department of Ophthalmology, Loyola University Medical Center, Maywood, Illinois; Cook County Health and Hospitals System, Department of Ophthalmology, Chicago, Illinois. Electronic address: veena.raiji@gmail.com.

PMID: 33509565
DOI: 10.1016/j.disamonth.2021.101143

No abstract available

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Diabetes Mellitus*
Diabetic Retinopathy / pathology
Diabetic Retinopathy / therapy*
Humans
Intravitreal Injections*
Laser Therapy*
Lasers
Light Coagulation
Receptors, Vascular Endothelial Growth Factor / administration & dosage
Receptors, Vascular Endothelial Growth Factor / therapeutic use
Recombinant Fusion Proteins / administration & dosage
Recombinant Fusion Proteins / therapeutic use
Steroids / administration & dosage
Steroids / therapeutic use*
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Recombinant Fusion Proteins
Steroids
Vascular Endothelial Growth Factor A
aflibercept
Receptors, Vascular Endothelial Growth Factor